Although the use of hormone inhibitors, such as tamoxifen, fulvestrant, and aromatase inhibitors, has remained the mainstay of ER + breast cancer treatment, the emergence of resistance has led to the addition of CDK4/6 inhibitors to this therapy. The gene discussed is CDK4; the disease is breast carcinoma.